Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Claims Update Pharmacy topic
No spam. Unsubscribe anytime.
Harlingen CISD benefits staff: GLP-1 drugs were miscoded by carrier; $800,000 credit and a 2022 claim reimbursement will improve projections
Summary
Benefits staff told Harlingen CISD’s benefits committee that a carrier coding error led to GLP-1 (weight-management) prescriptions being included in pharmacy claims, and that Blue Cross has fixed the error and is expected to return roughly $800,000; staff also expects a reimbursement of about $625,000 on a 2022 claim related to stop-loss limits.
District benefits staff told the Harlingen CISD benefits committee that recent pharmacy-cost growth reflected two accounting issues that will materially improve the district’s near-term fund projections once corrected.
Scott Gibbs, a benefits consultant, reported that Blue Cross had misapplied benefit configuration for GLP-1 medications (weight-management exclusion settings), which caused the district’s pharmacy claims to include prescriptions intended to be excluded. “They checked the wrong box,” Gibbs said. Staff said Blue Cross fixed the coding and the district expects a reimbursement in the neighborhood of $800,000 once January claims are corrected and the carrier completes its adjustments.
In addition, staff reported a long-outstanding in-network claim from 2022 of approximately $625,000 that initially fell outside reinsurance limits because of how it was paid. Benefits staff told the committee they reached agreement with the carrier on reimbursement over the district’s stop-loss threshold and expect a recovery to be paid within roughly 60 days.
Benefits staff said the combined effect of the pharmacy correction and the stop-loss reimbursement would reduce the projected deficit for the current plan year; updated projections and corrected claims data will be circulated to committee members and to the board before the August 5 meeting. The presenter noted pharmacy script counts and cost-per-script analyses show GLP-1 agents (examples cited include semaglutide and related products) were leading the pharmacy trend and that correcting the coding will lower the pharmacy trend from the roughly 16–20% increase reported to a figure closer to industry norms.
The committee also discussed utilization protocols: consultants said the district’s policy requires GLP-1 coverage only for Type 2 diabetes with an A1C threshold (consultant cited A1C greater than 6.01) and that Prime Therapeutics and Blue Cross are applying utilization-management protocols consistent with that policy going forward.
No formal decisions were recorded in committee; staff will re-run the projections with corrected claims and distribute the updated numbers to the committee and board prior to the board agenda date.
